Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response (NCT06175000)
Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete or Partial Responders
🩺 Plain-English Summary (8th-Grade Level)
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
Who can join: Review the eligibility criteria below.
Location: Memorial Sloan Kettering Cancer Center — New York, New York
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Memorial Sloan Kettering Cancer Center — New York, New York
- Cleveland Clinic — Cleveland, Ohio
- Providence Health & Services; Providence Neurological Specialties — Portland, Oregon
- Pennsylvania State University — Hershey, Pennsylvania
- University of Vermont — Burlington, Vermont
- University of Virginia — Charlottesville, Virginia
- Ivy Center for Advanced Brain Tumor Treatment; Swedish Neuroscience Institute — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (503) 216-1023
Email: tiffany.gervasi-follmar@providence.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Primary Central Nervous System Lymphoma
- Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma — Bethesda, Maryland
- Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma — St Louis, Missouri
- Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL — Boston, Massachusetts
- Pembrolizumab, Ibrutinib and Rituximab in PCNSL — Boston, Massachusetts
- Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas — Miami, Florida
Explore by condition: All Primary Central Nervous System Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.